(3,5-difluoropyridin-4-yl)methyl methanesulfonate | 1372891-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (3,5-difluoropyridin-4-yl)methyl methanesulfonate
• 英文别名: (3,5-Difluoropyridin-4-yl)methyl methanesulphonate
• CAS: 1372891-56-9
• 化学式: C₇H₇F₂NO₃S
• 分子量: 223.2
• InChiKey: UXBHUHOWZJYZQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (3,5-difluoropyridin-4-yl)methyl methanesulfonate 在 sodium iodide 作用下， 以 四氢呋喃 为溶剂， 反应 15.07h， 生成 10-[(3,5-difluoropyridin-4-yl)methyl]-10-[(pyridazin-4-yl)methyl]-9,10-hydroanthracen-9-one
  参考文献：
  名称：

  An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders

  摘要：

  A set of novel Kv7.2/7.3 (KCNQ2/3) channel blockers was synthesized to address several liabilities of the known compounds XE991 (metabolic instability and CYP inhibition) and the clinical compound DMP 543 (acid instability, insolubility, and lipophilicity). Using the anthrone scaffold of the prior channel blockers, alternative heteroarylmethyl substituents were installed via enolate alkylation reactions. Incorporation of a pyridazine and a fluorinated pyridine gave an analog (compound 18, JDP-107) with a promising combination of potency (IC50=0.16 mu M in a Kv7.2 thallium flux assay), efficacy in a Kv7.2/7.3 patch clamp assay, and drug-like properties.

  DOI：

  10.1016/j.bmcl.2019.126681
• 作为产物：
  描述：

  3,5-二氟吡啶-4-甲酸 在 10-[(3,5-difluoropyridin-4-yl)methyl]-10-[(pyridazin-4-yl)methyl]-9,10-hydroanthracen-9-one 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.25h， 生成 (3,5-difluoropyridin-4-yl)methyl methanesulfonate
  参考文献：
  名称：

  An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders

  摘要：

  A set of novel Kv7.2/7.3 (KCNQ2/3) channel blockers was synthesized to address several liabilities of the known compounds XE991 (metabolic instability and CYP inhibition) and the clinical compound DMP 543 (acid instability, insolubility, and lipophilicity). Using the anthrone scaffold of the prior channel blockers, alternative heteroarylmethyl substituents were installed via enolate alkylation reactions. Incorporation of a pyridazine and a fluorinated pyridine gave an analog (compound 18, JDP-107) with a promising combination of potency (IC50=0.16 mu M in a Kv7.2 thallium flux assay), efficacy in a Kv7.2/7.3 patch clamp assay, and drug-like properties.

  DOI：

  10.1016/j.bmcl.2019.126681

文献信息

• [EN] TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5<br/>[FR] MODULATEURS TÉTRAHYDRO-BENZOIMIDAZOLYLES DE TGR5
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015160772A1

  公开（公告）日：2015-10-22

  The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1and Z2 are defined in the specification.

  本发明包括式（I）的化合物。其中：R1、R2、R3、R4、R5、R6、R7、R8、X、Z1和Z2在规范中定义。
• HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS
  申请人：Follmann Markus

  公开号：US20140228366A1

  公开（公告）日：2014-08-14

  The present application relates to novel heteroaryl-substituted pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新颖的杂环芳基取代的吡唑吡啶衍生物，其制备方法，它们单独或组合用于治疗和/或预防疾病，以及它们用于制备用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS
  申请人：Castro Pichel Julia

  公开号：US20130203802A1

  公开（公告）日：2013-08-08

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR 5 ; or X is C and Y is S; Z is selected from N and CH; R 1 is selected from H and C 1-2 alkyl; R 2 is selected from H, C 1-2 alkyl, OH, —CH 2 OH and C 1-2 alkoxy; Each R 3 is independently selected from OH, C 1-3 alkyl, F, Cl, Br, NH 2 , and C 1-3 alkoxy; R 4 is selected from C 1-3 alkyl and haloC 1-3 alkyl; R 5 is selected from H, C 1-3 alkyl and haloC 1-3 alkyl; R 6 and R 7 are either i) each independently selected from H, C 1-3 alkyl and C 1-3 alkoxy; or ii) R 6 and R 7 together with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and R A is selected from H and C 1-3 alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  公式（I）的化合物或其药用盐：其中：Het是5至10成员的杂环芳香环；X为N且Y为CR5；或X为C且Y为S；Z从N和CH中选择；R1从H和C1-2烷基中选择；R2从H、C1-2烷基、OH、—CH2OH和C1-2烷氧基中选择；每个R3独立选择自OH、C1-3烷基、F、Cl、Br、NH2和C1-3烷氧基；R4从C1-3烷基和卤代C1-3烷基中选择；R5从H、C1-3烷基和卤代C1-3烷基中选择；R6和R7要么i）各自独立选择自H、C1-3烷基和C1-3烷氧基；要么ii）R6和R7与它们附着的环一起形成9成员双环环；p为0-3；RA从H和C1-3烷基中选择，提供了含有它们的组合物，它们在治疗中的使用，例如在结核病的治疗中，并提供了这类化合物的制备方法。
• Tetrahydro-benzoimidazolyl modulators of TGR5
  申请人：Janssen Pharmaceutica NV

  公开号：US10077241B2

  公开（公告）日：2018-09-18

  The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1 and Z2 are defined in the specification.

  本发明包括式（I）化合物。 其中 R1、R2、R3、R4、R5、R6、R7、R8、X、Z1 和 Z2 的定义见说明书。
• HETEROARYL-SUBSTITUIERTE PYRAZOLOPYRIDINE UND IHRE VERWENDUNG ALS STIMULATOREN DER LÖSLICHEN GUANYLATCYCLASE
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2729476B1

  公开（公告）日：2017-08-23